What do payers want in oncology diagnostics? Insights from a national survey of top commercial and Medicare health plans

American Health and Drug Benefits

Volumn 4, Issue 4 SPEC. ISSUE, 2011, Pages

  Trogan, Gene ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PANITUMUMAB;

BREAST CANCER; COLORECTAL CANCER; COST CONTROL; DIAGNOSTIC PROCEDURE; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH INSURANCE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NOTE; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT SELECTION; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 80052765950     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Reimbursement Intelligence. www.reimbursement_intelligence.com/2011_asco_special_report/. Accessed August 1, 2011.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
3. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(suppl 3):S1-S22.
4. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogenreceptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11:313-324. Erratum in Am J Manag Care. 2005;11:476.
5. Evans RW, Williams GE, Baron HM, et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant. 2005;5:1553-558.
6. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall- cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-2874.
7. US Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff. In vitro companion diagnostic devices. July 14, 2011. www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf. Accessed August 4, 2011.
8. Pothier K, Gustavsen G. How to earn the economic payback diagnostics companies deserve. In Vivo. 2009:70-75.
9. G2 Intelligence. CMS delays pricing new molecular pathology codes-questions remain for local contractors. 2011. www.g2intelligence.com/ezine/article/ART847115?channel=20110722_G2INSIDER. Accessed August 1, 2011